In the clinical trial that was stopped early, patients with ventilator-associated bacterial pneumonia received either 7-day Doribax treatment or 10-day treatment with imipenem and cilastatin, another antibacterial drug.1 In the intent-to-treat population, the 28-day all-cause mortality was higher in the Doribax arm (23.0 percent; n=31/135) than in the imipenem and cilastatin arm (16.7 percent; n=22/132) . Clinical cure rates were also lower in the Doribax arm.
En FDA
No hay comentarios:
Publicar un comentario